Cargando…
Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer
Cell therapy encompasses an expanding spectrum of cell-based regimes for the treatment of human ailments, such as the use of immune cells, in particular T cells, for combating tumors and the modulation of inflammatory immune responses. In this review, we focus on cell therapy in the immuno-oncology...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151952/ https://www.ncbi.nlm.nih.gov/pubmed/37100458 http://dx.doi.org/10.1136/jitc-2022-006434 |
_version_ | 1785035651643604992 |
---|---|
author | Neo, Shi Yong Xu, Shengli Chong, Joni Lam, Kong-Peng Wu, Jing |
author_facet | Neo, Shi Yong Xu, Shengli Chong, Joni Lam, Kong-Peng Wu, Jing |
author_sort | Neo, Shi Yong |
collection | PubMed |
description | Cell therapy encompasses an expanding spectrum of cell-based regimes for the treatment of human ailments, such as the use of immune cells, in particular T cells, for combating tumors and the modulation of inflammatory immune responses. In this review, we focus on cell therapy in the immuno-oncology space, which is largely driven by interests and demands from the clinics for better solutions to target various hard-to-treat cancers. We discuss recent advances in various types of cell therapies, including T cell receptor-T cells, chimeric antigen receptor (CAR)-T cells, tumor-infiltrating lymphocytes and natural killer cells. Particularly, the present review focuses on the strategies to improve therapeutic responses by either enhancing tumor recognition or the resilience of infused immune cells within tumor microenvironment. Finally, we discuss the potential of other innate or innate-like immune cell types currently being explored as promising CAR-cell alternatives that seek to address the limitations of conventional adoptive cell therapies. |
format | Online Article Text |
id | pubmed-10151952 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-101519522023-05-03 Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer Neo, Shi Yong Xu, Shengli Chong, Joni Lam, Kong-Peng Wu, Jing J Immunother Cancer Review Cell therapy encompasses an expanding spectrum of cell-based regimes for the treatment of human ailments, such as the use of immune cells, in particular T cells, for combating tumors and the modulation of inflammatory immune responses. In this review, we focus on cell therapy in the immuno-oncology space, which is largely driven by interests and demands from the clinics for better solutions to target various hard-to-treat cancers. We discuss recent advances in various types of cell therapies, including T cell receptor-T cells, chimeric antigen receptor (CAR)-T cells, tumor-infiltrating lymphocytes and natural killer cells. Particularly, the present review focuses on the strategies to improve therapeutic responses by either enhancing tumor recognition or the resilience of infused immune cells within tumor microenvironment. Finally, we discuss the potential of other innate or innate-like immune cell types currently being explored as promising CAR-cell alternatives that seek to address the limitations of conventional adoptive cell therapies. BMJ Publishing Group 2023-04-26 /pmc/articles/PMC10151952/ /pubmed/37100458 http://dx.doi.org/10.1136/jitc-2022-006434 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Review Neo, Shi Yong Xu, Shengli Chong, Joni Lam, Kong-Peng Wu, Jing Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer |
title | Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer |
title_full | Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer |
title_fullStr | Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer |
title_full_unstemmed | Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer |
title_short | Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer |
title_sort | harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151952/ https://www.ncbi.nlm.nih.gov/pubmed/37100458 http://dx.doi.org/10.1136/jitc-2022-006434 |
work_keys_str_mv | AT neoshiyong harnessingnovelstrategiesandcelltypestoovercomeimmunetoleranceduringadoptivecelltherapyincancer AT xushengli harnessingnovelstrategiesandcelltypestoovercomeimmunetoleranceduringadoptivecelltherapyincancer AT chongjoni harnessingnovelstrategiesandcelltypestoovercomeimmunetoleranceduringadoptivecelltherapyincancer AT lamkongpeng harnessingnovelstrategiesandcelltypestoovercomeimmunetoleranceduringadoptivecelltherapyincancer AT wujing harnessingnovelstrategiesandcelltypestoovercomeimmunetoleranceduringadoptivecelltherapyincancer |